- letzte 200 News
- Archiv
| Zeit | Aktuelle Nachrichten | Rating | Leser | ||
|---|---|---|---|---|---|
| Di | Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update | 92 | NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results... ► Artikel lesen | ||
| Di | Imunon, Inc.: IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study | 116 | IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2... ► Artikel lesen | ||
| Di | IZEA Worldwide, Inc.: IZEA Launches ZED: The Creator Economy Marketing Operations Platform Infused with AI | 126 | ORLANDO, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- IZEA Worldwide, Inc. (NASDAQ: IZEA), a full-service creator economy agency, today announced the launch of ZED, a creator economy marketing operations... ► Artikel lesen | ||
| Di | Tokyo Lifestyle Co., Ltd.: Tokyo Lifestyle Enters Health Product, Cosmetics and Liquors Sale and Purchase Agreement with TASLY HONG KONG to Expand Presence in China | 58 | Tokyo, Japan, March 31, 2026 (GLOBE NEWSWIRE) -- Tokyo Lifestyle Co., Ltd. ("Tokyo Lifestyle" or the "Company") (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry... ► Artikel lesen | ||
| Di | Catheter Precision, Inc.: Catheter Precision Reports 2025 Results and Updates on Strategic Expansion | 95 | Clinical, Commercial and Regulatory Milestones Achieved in 2025 Establish a Strong Foundation in Life Sciences as Revenue Increases 95% Year Over Year Acquisition of Flyte and Strengthened Capital... ► Artikel lesen | ||
| Di | Allarity Therapeutics, Inc.: Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress | 91 | Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for stenoparib... ► Artikel lesen | ||
| Di | Solésence, Inc.: Solésence Reports Fourth Quarter and Full-Year 2025 Financial Results | 172 | Full Year 2025 record revenue of $62.1 million ROMEOVILLE, Ill., March 31, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty... ► Artikel lesen | ||
| Di | Enzymatica AB: Enzymatica and STADA sign partnership agreement for Germany and Austria | 124 | Regulatory press release
• The new partnership agreement covers the launch and distribution of Enzymatica's ColdZyme® technology in oral spray form in Germany and Austria
• The partnership combines... ► Artikel lesen | ||
| Di | Park Street A/S - Annual Report 2025 | 49 | Park Street A/S - Annual Report 2025 Copenhagen, 31 March 2026 Park Street primarily uses EBVAT (Earnings before value adjustments and tax) as the key measure of the Group's operating performance.... ► Artikel lesen | ||
| Di | WW International Inc.: Weight Watchers Announces Best in Market Self-Pay Wegovy Pricing for Med+ Members and the Launch of Preferred Subscription Pricing for Wegovy via NovoCare | 156 | NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) ("Weight Watchers"), the global leader in science-backed weight health, today announced that eligible Weight Watchers... ► Artikel lesen | ||
| Di | NervGen Pharma Corp.: NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates | 134 | Completed End-of-Phase 2 meeting with the FDA; Company expects to provide a regulatory update in early 2Q 2026 and remains on track to initiate a Phase 3 study in chronic tetraplegia in mid-2026.... ► Artikel lesen | ||
| Di | Plus Therapeutics Inc.: Plus Therapeutics Announces Reverse Stock Split | 108 | HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies... ► Artikel lesen | ||
| Di | BrightSpring Health Services, Inc.: BrightSpring Health Services Completes Sale of ResCare Community Living to Sevita | 93 | LOUISVILLE, Ky., March 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based pharmacy and... ► Artikel lesen | ||
| Di | PMGC Holdings Inc.: AGA Precision Systems Signs Long-Term Agreement to Supply Mission-Critical Aerospace and Defense Components to Turbo-Jet Products | 101 | NEWPORT BEACH, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- AGA Precision Systems LLC ("AGA"), a precision aerospace manufacturing company and wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ:... ► Artikel lesen | ||
| Di | Rio Silver, Inc.: Rio Silver Closes $3.0M Private Placement with Eric Sprott as Lead Investor | 87 | VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- Rio Silver Inc. (the "Company" or "Rio Silver") (TSX.V: RYO) (OTC: RYOOF) is pleased to announce that it has closed its non-brokered... ► Artikel lesen | ||
| Di | Hypercharge Networks Corp.: Hypercharge Announces Appointment of Kyle Moncrief, CFA as VP, Corporate Development and FP&A, and Changes to Board of Directors | 87 | VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- Hypercharge Networks Corp. (TSXV: HC OTC: HCNWF- FSE: PB7) (the "Company" or "Hypercharge"), a leading, smart electric vehicle (EV)... ► Artikel lesen | ||
| Di | SAGA Metals Corp.: SAGA Metals Reports Assays from R-0021 to R-0023 with Intercepts Including 53.18% Fe2O3, 7.08% TiO2, 0.414% V2O5 from 2026 Drilling at Trapper South, Radar Critical Minerals Project in Labrador | 155 | VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- SAGA Metals Corp. ("SAGA" or the "Company") (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H), a North American exploration company focused on... ► Artikel lesen | ||
| Di | MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum | 91 | ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000-300,000 patients annually in US/EUC-Further Consortium collaboration adds to growing... ► Artikel lesen | ||
| Di | B.O.S. Better Online Solutions Ltd.: BOS Reports Financial Results for the Fourth Quarter and Full Year 2025 | 117 | Delivers Record Year Performance Provides Initial 2026 Revenue and Net Income Guidance RISHON LE ZION, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- BOS Better Online Solutions Ltd. (BOSC) today reported... ► Artikel lesen | ||
| Di | Palvella Therapeutics Inc.: Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update | 111 | New Drug Application (NDA) for QTORIN rapamycin for the treatment of microcystic lymphatic malformations (microcystic LMs) on track for planned submission in second half of 2026 Accelerating U.S.... ► Artikel lesen | ||
| Di | Geotab and Hyundai partner to deliver hardware-free, native telematics integration | 201 | Unlocking high-resolution GPS, proactive maintenance and EV insights directly via the cloud for Hyundai fleetsPARIS, March 31, 2026 (GLOBE NEWSWIRE) -- Geotab, a global leader in connected vehicle solutions... ► Artikel lesen | ||
| Di | Seyond Inc: Seyond Releases 2025 Annual Report | Inflection Point Emerges: Multi-Engine Growth Unlocks Unlimited Potential of Physical AI | 277 | SUNNYVALE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- On March 31, 2026, Seyond (02665.HK) announced its audited full-year results for 2025. During the reporting period, the company's annual lidar shipments... ► Artikel lesen | ||
| Di | Biogen Inc.: Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology | 347 | Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE FDA-approved... ► Artikel lesen | ||
| Di | Nexus Enterprises, Inc: Nexus Raises $4.3M Seed Round to Help Business Teams Deploy AI Agents | 300 | BRUSSELS and SAN FRANCISCO, March 31, 2026 (GLOBE NEWSWIRE) -- Nexus, an agentic AI platform enabling enterprises to deploy autonomous agents, today announced a $4.3 million seed funding round. The... ► Artikel lesen | ||
| Di | FactSet Research Systems Inc.: FactSet Reports Results for Second Quarter 2026 | 145 | Q2 GAAP revenues of $611.0 million, up 7.1% from Q2 2025.Organic ASV was $2,449.1 million at February 28, 2026, up 6.7% year over year.Q2 GAAP operating margin of 30.3%, down approximately 220 bps... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.